AngioDynamics Expands Patient Access to NanoKnife IRE for Prostate and Liver Cancer as Medicare Coverage Framework Takes Effect
Palmetto GBA issued a final Local Coverage Determination (LCD L40205) establishing Medicare coverage for AngioDynamics' NanoKnife IRE technology in favorable intermediate-risk prostate cancer and metastatic colorectal cancer to the liver. The coverage framework becomes effective July 5, 2026, building on Category I CPT codes activated by the AMA on January 1, 2026, which formalized the clinical value and billing standards for these procedures.
Key figures
- Lcd effective date
- July 5, 2026
- Cpt activation date
- January 1, 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.